REGISTER
How to balance the use of T-DXd
Prof. Curigliano and Prof. Tao discussed how to balance the use of T-DXd in the neoadjuvant versus adjuvant settings for HER2-positive early breast cancer.

Prof. Giuseppe Curigliano, European Institute of Oncology, Italy
Prof. Zhonghua Tao, Fudan University Shanghai Cancer Center, China

Prof. Curigliano and Prof. Tao discussed how to balance the use of T-DXd in the neoadjuvant versus adjuvant settings for HER2-positive early breast cancer, in light of emerging evidence from the DB-05 and DB-11 studies. They explored which patient characteristics and biomarkers may help guide clinical decision-making, and also shared perspectives on potential differences between Chinese and international patients.

0
0
Loading